Analyst Ratings For AzurRx BioPharma Inc (NASDAQ:AZRX)
Today, HC Wainwright reiterated its Buy rating on AzurRx BioPharma Inc (NASDAQ:AZRX) with a price target of $6.00.
There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on AzurRx BioPharma Inc (NASDAQ:AZRX) is Buy with a consensus target price of $6.00 per share, a potential 156.41% upside.
Some recent analyst ratings include
- 8/17/2018-AzurRx BioPharma Inc (NASDAQ:AZRX) had its Buy rating reiterated by HC Wainwright with a $6.00 price target
- 12/6/2016-AzurRx BioPharma Inc (NASDAQ:AZRX) has coverage initiated with a Buy rating and $7.00 price target
Recent Insider Trading Activity For AzurRx BioPharma Inc (NASDAQ:AZRX)
AzurRx BioPharma Inc (NASDAQ:AZRX) has insider ownership of 7.20% and institutional ownership of 8.62%.
- On 6/30/2017 Pelican Partners Llc, Major Shareholder, sold 160,000 with an average share price of $3.19 per share and the total transaction amounting to $510,400.00.
About AzurRx BioPharma Inc (NASDAQ:AZRX)
AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.
Recent Trading Activity for AzurRx BioPharma Inc (NASDAQ:AZRX)
Shares of AzurRx BioPharma Inc closed the previous trading session at 2.35 −0.025 1.05% with 2.4 shares trading hands.
